Thursday, October 15, 2026

Zoomex Secures US, Canada MSB Licenses as Crypto Exchanges Push Regulatory Compliance

Cryptocurrency exchange Zoomex has obtained Money Services Business licenses in both the United States and Canada, marking a significant compliance milestone in the crypto industry's push toward regulatory legitimization. The licensing expansion signals growing institutional acceptance of crypto trading infrastructure as exchanges seek to bridge traditional finance and digital assets.

LM Salvado
LM Salvado

April 16, 2026

Zoomex Secures US, Canada MSB Licenses as Crypto Exchanges Push Regulatory Compliance
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Zoomex has secured Money Services Business (MSB) licenses in the United States and Canada, joining a growing number of crypto exchanges pursuing regulatory approval to access mainstream financial markets.1

The dual-jurisdiction licensing represents a strategic shift in crypto exchange operations. MSB registration requires exchanges to implement anti-money laundering controls, customer identification procedures, and transaction monitoring systems that align with traditional banking standards.1

Zoomex also obtained licensing from Mantle, though specific operational details remain limited.1 The multi-jurisdictional approach reflects industry-wide recognition that regulatory compliance has become essential for institutional participation in crypto markets.

The licensing push comes as traditional financial institutions increase crypto infrastructure investments. Regulatory clarity in major markets like the US and Canada reduces operational risk for banks and asset managers considering crypto trading services.

Exchange legitimization through regulatory licensing addresses longstanding institutional concerns about counterparty risk and compliance liability. MSB status brings crypto platforms under the same supervisory framework as money transmitters and payment processors, creating familiar regulatory terrain for traditional finance players.

The timing aligns with broader institutional crypto adoption trends. Asset managers require exchanges to meet specific regulatory thresholds before directing client capital to digital asset trading platforms.

For retail investors, regulated exchange status provides additional consumer protections and oversight. MSB licensing mandates financial reporting, capital requirements, and operational transparency that unlicensed platforms often lack.

The regulatory expansion trend suggests crypto exchanges are prioritizing market access over the industry's historically libertarian stance on financial regulation. Compliance costs and operational restrictions are increasingly viewed as acceptable trade-offs for institutional capital inflows.

Traditional finance integration with crypto platforms will likely accelerate through 2026 as more exchanges complete regulatory processes in key jurisdictions. The infrastructure gap between legacy banking systems and crypto markets continues to narrow as exchanges adopt conventional financial controls.

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com